엔도뉴클레아제 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of endonucleases Market

The global endonucleases market was valued at USD 193.43 million in 2025 and is projected to grow from USD 209.34 million in 2026 to USD 407.15 million by 2034, registering a CAGR of 8.67% during the forecast period (2026-2034). North America dominated the global market with a 46.87% market share in 2025, supported by advanced biotechnology infrastructure, increasing genomic research, and strong investments in gene-editing technologies.

Endonucleases are enzymes that cut DNA at specific internal sites and play a vital role in molecular biology, genetic engineering, recombinant DNA technology, diagnostics, and gene therapy. The growing demand for CRISPR-based genome editing, personalized medicine, and precision genomics is significantly driving market expansion. Continuous investments in biotechnology research and the increasing number of gene-editing clinical trials are further accelerating industry growth.

Market Drivers

Technological Advancements in Gene Editing Fuel Market Growth

Rapid advancements in CRISPR-Cas gene-editing technologies are among the primary factors driving the endonucleases market. Modern high-fidelity endonucleases improve editing precision while reducing off-target effects, making them increasingly valuable for therapeutic applications and scientific research.

The increasing number of gene-editing clinical trials worldwide has also strengthened demand for high-quality endonucleases. Pharmaceutical companies, biotechnology firms, and academic institutions continue to expand research activities involving DNA modification, cell therapy, and genetic engineering, creating sustained demand for advanced enzyme products.

Market Restraints

Regulatory and Ethical Challenges Limit Commercial Adoption

Despite strong technological progress, regulatory approval remains a major challenge. Ethical concerns surrounding human genome editing have resulted in stringent regulations and lengthy approval procedures in many countries.

In addition, concerns regarding unintended genetic modifications and long-term safety continue to delay commercialization of certain genome-editing therapies, restricting broader market growth.

Market Opportunities

Personalized Medicine Creates Significant Growth Potential

The increasing adoption of precision medicine presents major opportunities for endonuclease manufacturers. These enzymes enable highly targeted DNA modifications that support personalized therapeutic approaches.

Growing collaborations between biotechnology companies, pharmaceutical manufacturers, and research organizations are further expanding the clinical applications of endonucleases in cancer treatment, rare genetic disorders, and autoimmune diseases. As personalized medicine becomes more mainstream, demand for advanced genome-editing enzymes is expected to rise substantially.

Market Trends

CRISPR-Based Diagnostics Emerging as a Key Industry Trend

One of the most significant trends shaping the market is the rapid adoption of CRISPR-based diagnostic technologies. Compared to conventional PCR methods, CRISPR diagnostics provide faster detection, higher specificity, and greater sensitivity for identifying infectious diseases and genetic disorders.

These technologies are increasingly being incorporated into next-generation molecular diagnostic platforms, supporting faster clinical decision-making and expanding the commercial applications of endonucleases.

Segmentation Analysis

By Type

Specific endonucleases accounted for the largest market share owing to their widespread application in molecular biology, genomics research, and CRISPR gene-editing technologies. Restriction enzymes and CRISPR-Cas nucleases continue to dominate due to their high precision and broad research applications.

By Application

Genomics and genetic engineering represented the leading application segment in 2024. Increasing adoption of CRISPR technologies, rising approvals for gene and cell therapies, and expanding research activities continue to strengthen this segment.

Drug discovery and research is also expected to witness significant growth throughout the forecast period as pharmaceutical companies increasingly adopt genome-editing technologies.

By Source

The prokaryotic segment remained dominant because of its extensive use in synthetic biology, molecular biology research, and commercial biotechnology applications. Numerous leading biotechnology companies continue expanding their portfolios of prokaryotic-derived endonucleases.

By End User

Pharmaceutical and biotechnology companies held the largest market share due to increasing investments in gene therapy, biologics development, and precision medicine research. Academic and research institutes also continue to generate steady demand through expanding genomic research programs.

Regional Insights

North America remained the largest regional market, reaching USD 90.67 million in 2025 and projected to grow to USD 97.48 million in 2026. The region benefits from strong biotechnology infrastructure, extensive research funding, and widespread adoption of advanced molecular biology technologies.

Europe generated USD 53.30 million in 2025 and is expected to reach USD 57.94 million in 2026, supported by growing genomic medicine adoption and innovation clusters across major European countries.

Asia Pacific accounted for USD 35.62 million in 2025 and is forecast to reach USD 39.18 million in 2026. Expanding biotechnology research, increasing investments in genomics, and growing pharmaceutical industries in China, Japan, and India continue driving regional growth.

Latin America and the Middle East & Africa are expected to witness moderate growth during the forecast period due to increasing biotechnology investments and expanding genomics research capabilities.

Competitive Landscape

The global endonucleases market is moderately fragmented, with major companies focusing on product innovation, strategic partnerships, geographic expansion, and broader enzyme portfolios to strengthen their market positions.

Key companies operating in the market include:

• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• New England Biolabs
• Promega Corporation
• QIAGEN
• Agilent Technologies Inc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd.

Recent product launches, commercialization of CRISPR-based nucleases, and strategic collaborations continue to intensify competition across the global market.

Key Industry Developments

• July 2025: New England Biolabs launched Monarch DNase I in a lyophilized formulation for genomic DNA removal from RNA samples.
• May 2025: Biomay AG introduced its FDA-grade CRISPR/Cas9 nuclease for commercial genome-editing applications.
• January 2023: Aldevron LLC launched Eureca-V Nuclease for diagnostic, therapeutic, and agricultural workflows.
• January 2023: Agilent Technologies invested approximately USD 725 million to expand therapeutic nucleic acid manufacturing capacity.
• October 2021: Krishgen Biosystems introduced the Endonuclease S. marcescens ELISA for quantitative enzyme detection.

Conclusion

The global endonucleases market is expected to witness robust growth between 2026 and 2034, driven by the rapid advancement of CRISPR technologies, increasing genomic research, expanding personalized medicine applications, and growing investments in biotechnology. Rising demand from pharmaceutical companies, research institutes, and diagnostic developers will continue supporting market expansion. Although regulatory challenges and ethical concerns remain important barriers, continuous technological innovation and broader clinical adoption are expected to position endonucleases as a critical component of next-generation gene-editing and molecular diagnostic solutions.

Segmentation By Type

• Specific Endonucleases
  • Restriction Enzymes
  • CRISPR-Cas Nucleases
  • Others
• Non-specific Endonucleases
  • DNases
  • RNases
  • Others

By Application

• Genomics & Genetic Engineering
• Drug Discovery & Research
• Molecular Biology
• Others

By Source

• Prokaryotic
• Eukaryotic
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes
• Others

By Geography

• North America (By Type, Application, Source, End User, and Country)
  • U.S.
  • Canada
• Europe (By Type, Application, Source, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Application, Source, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Application, Source, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Application, Source, End User, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in DNA Modification Techniques
• 4.2. Technological Advancements in Genetic Engineering
• 4.3. New Product Launches, By Key Players
• 4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
• 4.5. Overview: Key Start-ups in CRISPR-based Therapeutics

5. Global Endonucleases Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Specific Endonucleases
    • 5.1.1.1. Restriction enzymes
    • 5.1.1.2. CRISPR-Cas nucleases
    • 5.1.1.3. Others
  • 5.1.2. Non-specific Endonucleases
    • 5.1.2.1. DNases
    • 5.1.2.2. RNases
    • 5.1.2.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Genomics & Genetic Engineering
  • 5.2.2. Drug Discovery & Research
  • 5.2.3. Molecular Biology
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Source
  • 5.3.1. Prokaryotic
  • 5.3.2. Eukaryotic
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Pharmaceutical and Biotechnology Companies
  • 5.4.2. Academic & Research Institutes
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Endonucleases Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Specific Endonucleases
    • 6.1.1.1. Restriction enzymes
    • 6.1.1.2. CRISPR-Cas nucleases
    • 6.1.1.3. Others
  • 6.1.2. Non-specific Endonucleases
    • 6.1.2.1. DNases
    • 6.1.2.2. RNases
    • 6.1.2.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Genomics & Genetic Engineering
  • 6.2.2. Drug Discovery & Research
  • 6.2.3. Molecular Biology
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Source
  • 6.3.1. Prokaryotic
  • 6.3.2. Eukaryotic
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Pharmaceutical and Biotechnology Companies
  • 6.4.2. Academic & Research Institutes
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Endonucleases Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Specific Endonucleases
    • 7.1.1.1. Restriction enzymes
    • 7.1.1.2. CRISPR-Cas nucleases
    • 7.1.1.3. Others
  • 7.1.2. Non-specific Endonucleases
    • 7.1.2.1. DNases
    • 7.1.2.2. RNases
    • 7.1.2.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Genomics & Genetic Engineering
  • 7.2.2. Drug Discovery & Research
  • 7.2.3. Molecular Biology
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Source
  • 7.3.1. Prokaryotic
  • 7.3.2. Eukaryotic
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Pharmaceutical and Biotechnology Companies
  • 7.4.2. Academic & Research Institutes
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Endonucleases Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Specific Endonucleases
    • 8.1.1.1. Restriction enzymes
    • 8.1.1.2. CRISPR-Cas nucleases
    • 8.1.1.3. Others
  • 8.1.2. Non-specific Endonucleases
    • 8.1.2.1. DNases
    • 8.1.2.2. RNases
    • 8.1.2.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Genomics & Genetic Engineering
  • 8.2.2. Drug Discovery & Research
  • 8.2.3. Molecular Biology
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Source
  • 8.3.1. Prokaryotic
  • 8.3.2. Eukaryotic
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Pharmaceutical and Biotechnology Companies
  • 8.4.2. Academic & Research Institutes
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Endonucleases Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Specific Endonucleases
    • 9.1.1.1. Restriction enzymes
    • 9.1.1.2. CRISPR-Cas nucleases
    • 9.1.1.3. Others
  • 9.1.2. Non-specific Endonucleases
    • 9.1.2.1. DNases
    • 9.1.2.2. RNases
    • 9.1.2.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Genomics & Genetic Engineering
  • 9.2.2. Drug Discovery & Research
  • 9.2.3. Molecular Biology
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Source
  • 9.3.1. Prokaryotic
  • 9.3.2. Eukaryotic
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Pharmaceutical and Biotechnology Companies
  • 9.4.2. Academic & Research Institutes
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Endonucleases Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Specific Endonucleases
    • 10.1.1.1. Restriction enzymes
    • 10.1.1.2. CRISPR-Cas nucleases
    • 10.1.1.3. Others
  • 10.1.2. Non-specific Endonucleases
    • 10.1.2.1. DNases
    • 10.1.2.2. RNases
    • 10.1.2.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Genomics & Genetic Engineering
  • 10.2.2. Drug Discovery & Research
  • 10.2.3. Molecular Biology
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Source
  • 10.3.1. Prokaryotic
  • 10.3.2. Eukaryotic
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Pharmaceutical and Biotechnology Companies
  • 10.4.2. Academic & Research Institutes
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. New England Biolabs
  • 11.2.2. Promega Corporation
  • 11.2.3. Thermo Fisher Scientific Inc.
  • 11.2.4. Takara Bio Inc.
  • 11.2.5. QIAGEN
  • 11.2.6. Agilent Technologies Inc.
  • 11.2.7. Merck KGaA
  • 11.2.8. F. Hoffmann-La Roche Ltd